Table III.

The percentage of patients who achieved an erythroid response over the 53/55-week study classified by baseline eEPO.

	ESA-naïve	Prior ESA-treated
Patients achieving an erythroid response, n (%)*
Baseline eEPO <100 mU/ml	58 (60) (n = 97)	12 (30) (n = 40)
Baseline eEPO ≥100 mU/ml and <500 mU/ml	13 (43) (n = 30)	2 (15) (n = 13)
Baseline eEPO ≥500 mU/ml	2 (14) (n = 14)	2 (29) (n = 7)

ESA, erythropoiesis-stimulating agent; eEPO, endogenous erythropoietin.

*Erythroid response was defined as an initial increase in haemoglobin of ≥15 g/l from baseline (in the absence of an RBC transfusion within the preceding 28 d) and an average increase in haemoglobin of ≥15 g/l from baseline that was sustained for at least 8 weeks following the initial rise.